Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy CSL (CSL) shares
Learn how to easily invest in CSL shares.
CSL Ltd (CSL) is a leading biotechnology business based in Australia. It opened the day at AUDA$292.6 after a previous close of AUDA$292.5. During the day the price has varied from a low of AUDA$291.95 to a high of AUDA$301.55. The latest price was AUDA$299.34 (25 minute delay). CSL is listed on the Australian Securities Exchange (ASX) and employs 25,000 staff. All prices are listed in Australian Dollars.
How to buy shares in CSL
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CSL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Compare trading platforms with Australian shares and ETFs
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How has Coronavirus impacted CSL's stock price?
Since the stock market crash in March caused by coronavirus, CSL's stock price has had significant negative movement.
Its last market close was A$292.5, which is 13.05% down on its pre-crash value of A$336.4 and 20.53% up on the lowest point reached during the March crash when the stocks fell as low as A$242.67.
If you had bought A$1,000 worth of CSL stocks at the start of February 2020, those stocks would have been worth A$905.99 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth A$938.93.
CSL shares at a glance
|52-week range||A$238.78 - A$318.02|
|50-day moving average||A$282.39|
|200-day moving average||A$277.72|
|Wall St. target price||A$314.57|
|Dividend yield||A$2.22 (0.97%)|
|Earnings per share (TTM)||A$7.17|
CSL stock price (Australian Securities Exchange (ASX):CSL)Use our graph to track the performance of CSL stocks over time.
CSL price performance over time
|1 week (2022-08-10)||2.39%|
|1 month (2022-07-18)||0.90%|
|3 months (2022-05-18)||9.61%|
|6 months (2022-02-18)||12.72%|
|1 year (2021-08-18)||1.97%|
|2 years (2020-08-18)||2.06%|
|3 years (2019-08-16)||31.64%|
|5 years (2017-08-17)||135.70%|
Is CSL under- or over-valued?
Valuing CSL stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CSL's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CSL's P/E ratio
CSL's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, CSL shares trade at around 41x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
CSL's EBITDA (earnings before interest, taxes, depreciation and amortisation) is A$3.4 billion.
The EBITDA is a measure of a CSL's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||A$10.6 billion|
|Operating margin TTM||28.31%|
|Gross profit TTM||A$5.8 billion|
|Return on assets TTM||9.13%|
|Return on equity TTM||20.96%|
|Market capitalisation||A$141.1 billion|
TTM: trailing 12 months
CSL's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like CSL.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
CSL's total ESG risk score
Total ESG risk: 27.73
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and CSL's overall score of 27.73 (as at 01/01/2019) is pretty good – landing it in it in the 40th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like CSL is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
CSL's environmental score
Environmental score: 3.04/100
CSL's environmental score of 3.04 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that CSL is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
CSL's social score
Social score: 18.57/100
CSL's social score of 18.57 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that CSL is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
CSL's governance score
Governance score: 11.12/100
CSL's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that CSL is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
CSL's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. CSL scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that CSL has, for the most part, managed to keep its nose clean.
CSL share dividends
Dividend payout ratio: 43.25% of net profits
Recently CSL has paid out, on average, around 43.25% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.97% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), CSL shareholders could enjoy a 0.97% return on their shares, in the form of dividend payments. In CSL's case, that would currently equate to about A$2.22 per share.
While CSL's payout ratio might seem fairly standard, it's worth remembering that CSL may be investing much of the rest of its net profits in future growth.
The latest dividend was paid out to all shareholders who bought their shares by 7 March 2022 (the "ex-dividend date").
Have CSL's shares ever split?
CSL's shares were split on a 3:1 basis on 18 October 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your CSL shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for CSL shares which in turn could have impacted CSL's share price.
CSL share price volatility
Over the last 12 months, CSL's shares have ranged in value from as little as A$238.7774 up to A$318.0184. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while CSL's is 0.1618. This would suggest that CSL's shares are less volatile than average (for this exchange).
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia. .
Frequently asked questions
CSL in the news
CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks
CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)
CSL announces carbon emissions reduction targets
More guides on Finder
How to buy AMTD Digital (HKD) shares
Steps to owning and managing HKD/USD, with 24-hour and historical pricing before you buy.
5 best stock trading apps in New Zealand (2022)
An overview of the best investing apps available in NZ, including pros, cons and fees.
Rockfort Markets share trading review
Your detailed review of share trading with Rockfort Markets, including fees, safety, and pros and cons.
5 of the best ways to invest money in New Zealand in 2022
What’s the best way to invest money in New Zealand? Find out about KiwiSaver, index funds, cryptocurrency and more in this guide.
BlackBull Markets share trading review
Your detailed review of share trading with BlackBull Markets, including brokerage fees, safety, pros and cons, and more.
Jarden Direct Share Trading review
Thinking of trading shares with Jarden Direct? Check out our review of Jarden Direct fees, safety, and pros and cons first.
Tiger Brokers share trading review
Your detailed review of online share trading with Tiger Brokers, including fees, markets, safety, pros and cons, and how to sign up.
Investor influx: 1 in 4 Kiwis are using share trading platforms
A growing number of Kiwis are investing in the stock market via an app or online platform, according to research by Finder.
How to buy Valkyrie Bitcoin Strategy ETF (BTF) from New Zealand
The second Bitcoin future ETF is set to go live Oct. 22. Here’s how to invest if you’re in New Zealand.
How to buy VanEck Bitcoin Strategy ETF units from New Zealand
Steps to owning and managing VanEck Bitcoin Strategy ETF units.